The diagnosis of brain tumor in children has been a matter of stinging concern in the medical fraternity. The research history in this regard has traced a long trajectory encompassing comprehensive analysis and wide testing. There is finally a ray of hope penetrating the medical frontier as Oncotarget sheds light on important findings offering potential cure for serious pediatric tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastom. Simone Treiger Sredni, MD, PhD, Associate Professor of Pediatric Neurosurgery at Northwestern University Feinburg School of Medicine, expressed his contentment over this breakthrough.

Inhibiting Attack on PLK4 Enzyme

The attack on the PLK4 enzyme by various agents is the root cause of pediatric brain tumor and the new treatment strategy focuses on dismissing these attacks. (AT/RT) is a fatal tumor that hasn’t been subjected to successful treatments so far. Similarly, Meduloblastoma is also a tumor occurring frequently in children and its current treatments are extremely toxic. Sredni believes that the strategic treatment of protecting PLK4, when hybridized with chemotherapy agents, will alleviate this toxicity as well.

How Does the New Treatment Strategy Function?

PLK4 inhibits the growth of tumors and even tones its propensity to metastasize. In pediatric brains, PLK4 becomes the target agent for tumors as well as cancer cells. The current findings have procured a drug that would prevent PLK4 from any attack by the tumor-causing agents. Further, the drug can be orally administered in children and would still cross the blood-brain barrier to evict the presence of cancer cells in pediatric nervous system. The drug was previously tested to prevent tumor growth in Vitro but has now rendered similar results amongst animals as well.